Journal article

Use of antidepressants with pharmacogenetic prescribing guidelines in a 10-year depression cohort of adult primary care patients

CD Jessel, S Mostafa, M Potiriadis, IP Everall, JM Gunn, CA Bousman

Pharmacogenetics and Genomics | LIPPINCOTT WILLIAMS & WILKINS | Published : 2020

Abstract

Objective To describe the usage patterns of antidepressants with published CYP2D6-and CYP2C19-based prescribing guidelines among depressed primary care patients and estimate the proportion of patients taking antidepressants not recommended for them based on their CYP2C19 and CYP2D6 genotype-predicted metabolizer status. Methods Medication use and pharmacogenetic testing results were collected on 128 primary care patients enrolled in a 10-year depression cohort study. At each 12-month interval, we calculated the proportion of patients that: (1) reported use of one or more of the 13 antidepressant medications (i.e. amitriptyline, citalopram, escitalopram, clomipramine, desipramine, doxepin, fl..

View full abstract

University of Melbourne Researchers

Grants

Awarded by National Health and Medical Research Council


Funding Acknowledgements

This research was funded by a grant awarded by the L.E.W. Carty Charitable Fund. The diamond study was initiated with pilot funding from the Beyondblue Victorian Centre of Excellence and the main cohort study has received Project Grant funding from the National Health and Medical Research Council (ID 299869, 454463, 566511, and 1002908). The 1-year Computer Assisted Telephone Interview was funded by a Stream 3 grant from the Australian Primary Health Care Research Institute (APHCRI). No funding body had a role in study design; the collection, analysis, and interpretation of data; the writing of the manuscript; or the decision to submit this manuscript for publication.